|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||13.81 - 14.12|
|52 Week Range||9.14 - 19.48|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||22.30|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Corcept Therapeutics Incorporated (CORT) filed a complaint against the company's officers and directors for breaches of fiduciary duty, insider selling and misappropriation of information, waste of corporate assets, and violations of the Securities Exchange Act of 1934 between August 2, 2017 and February 5, 2019. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effect of cortisol. Corcept's drug Korylm is a cortisol receptor blocker used to control hyperglycemia.
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Kimberly Park has joined the company’s Board of Directors. “I am very happy to welcome Kim to our Board,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.
Attractive stocks have exceptional fundamentals. In the case of Corcept Therapeutics Incorporated (NASDAQ:CORT...
Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the administration of Korlym® with food. The patent will expire in November 2032. “This patent covers an important finding of our research – that for optimal effect, Korlym must be taken with food,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. Upon issuance, Corcept plans to list the patent, entitled “Optimizing Mifepristone Absorption” (U.S. Pat.
Joseph Belanoff has been the CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT) since 1999. First, this article...
Corcept (CORT) delivered earnings and revenue surprises of 38.89% and -0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif., Aug. 01, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat.
If you're interested in Corcept Therapeutics Incorporated (NASDAQ:CORT), then you might want to consider its beta (a...
MENLO PARK, Calif., July 25, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate.
If you want to know who really controls Corcept Therapeutics Incorporated (NASDAQ:CORT), then you'll have to look at...
Looking at Corcept Therapeutics Incorporated's (NASDAQ:CORT) earnings update in March 2019, the consensus outlook from...
Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding ...
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Abraxane®) in patients with solid tumors, at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois (May 31 – June 4). “Encouraging results in patients with platinum-resistant ovarian cancer prompted us, after consultation with our investigators, to initiate a 180-patient, controlled Phase 2 trial of relacorilant plus nab-paclitaxel in that indication earlier this year.
SAN DIEGO, CA / ACCESSWIRE / May 20, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) shares. Investors, ...
NEW YORK, May 16, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Corcept Therapeutics.